3Sato A, Ito T, Tomita T, et al. Chemotherapy of gastric cancer-a review of clinical trials in Japan [J]. Gan To Kagaku Ryoho, 2002, 29 (9): 1522.
4Tanaka F, Fukuse T, Wada H, et al. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents [J]. Curt Pharm Biotechnol, 2000, 1 (2): 137.
5Terashima M, Fujiwara H, Takagane A, et al. Prediction of sensitivity of fluoropyrimidines by metabolic and target enzyme activities in gastric cancer [J]. Gastric Cancer, 2003, 6 (Suppl 1): 71.
6Yoshisue K, Hironaga K, Yamaguchi S, et al. Reduction of 5- fluorouracil gastroiontestinal toxicity resulting from the prtection of thymidylate synthase in gastrointestinal tissue by repeated simultaneous administration of potassium oxonate in rats [J]. Cancer ChemotherPharmacol, 2000, 46 (1): 51.
7Yoshisue K, Masuda H, Matsushima E, et al. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent(drug combination of tegafur, 5- chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats[J]. Drug Metab Dispos, 2000,28 (10) : 1162.
5Alberts SR, Cervantes A, VANDE Velde C J, et al. Gastric cancer : epi- demiology, pathology and treatment [ J] .Ann Oncol, 2003, 14 (suppl) :$31.
6Malet-Martino M, Martino R. Clinical studies of three oral pradrugs of 5-fluorouraeil ( eapecitabine, UFr, S-I ) : a review [ J ]. Oneologist, 2002, 7(4) :288 -323.
7Wasaburo K, Hiroyuki N, TaKuo H, et al. GotohM : SI plus cisplatin ver- sus SI alone for first-line treatment of advanced gastric cancer( SPIR- ITS trial) : a phase BI trial [ J ]. Lancet Oncol, 2008,9 ( 3 ) : 215 - 221.
8Nagashima F. Ohtsu A. yoshida S, et al. Janpanese nation wide post- marketing survey of S-1 in patients with advanced gastric cancer [ J ]. Gastric Cancer,2005,8 ( 1 ) :6 - 11.
9Maehara Y. S-1 in gastric cancer: A comprehensive review[ J]. Gastric Cancer,2003,6( Suppl 1 ) :2 - 8.
